Literature DB >> 20600601

Zonisamide reduces cell death in SH-SY5Y cells via an anti-apoptotic effect and by upregulating MnSOD.

Sumihiro Kawajiri1, Yutaka Machida, Shinji Saiki, Shigeto Sato, Nobutaka Hattori.   

Abstract

Zonisamide, originally known as an antiepileptic drug, has been approved in Japan as adjunctive therapy with levodopa for the treatment of Parkinson's disease (PD). Although zonisamide reduces neurotoxicity, the precise mechanism of this action is not known. Here, we show that zonisamide increases cell viability in SH-SY5Y cells via an anti-apoptotic effect and by upregulating levels of manganese superoxide dismutase (MnSOD). These results would give us novel evidences of PD treatment. Copyright 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20600601     DOI: 10.1016/j.neulet.2010.06.058

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  12 in total

Review 1.  Neuroprotection as a Potential Therapeutic Perspective in Neurodegenerative Diseases: Focus on Antiepileptic Drugs.

Authors:  D Caccamo; L R Pisani; P Mazzocchetti; R Ientile; P Calabresi; F Pisani; C Costa
Journal:  Neurochem Res       Date:  2015-12-31       Impact factor: 3.996

Review 2.  T-type calcium channel blockers as neuroprotective agents.

Authors:  Benjamin J Kopecky; Ruqiang Liang; Jianxin Bao
Journal:  Pflugers Arch       Date:  2014-02-25       Impact factor: 3.657

3.  HRD1 levels increased by zonisamide prevented cell death and caspase-3 activation caused by endoplasmic reticulum stress in SH-SY5Y cells.

Authors:  Tomohiro Omura; Masaru Asari; Joe Yamamoto; Naoya Kamiyama; Kumiko Oka; Chisato Hoshina; Chikatoshi Maseda; Toshio Awaya; Yoshikazu Tasaki; Hiroshi Shiono; Keiko Shimizu; Kazuo Matsubara
Journal:  J Mol Neurosci       Date:  2011-09-03       Impact factor: 3.444

4.  Protective effects of zonisamide against rotenone-induced neurotoxicity.

Authors:  Salvatore Condello; Monica Currò; Nadia Ferlazzo; Gregorio Costa; Giuseppa Visalli; Daniela Caccamo; Laura Rosa Pisani; Cinzia Costa; Paolo Calabresi; Riccardo Ientile; Francesco Pisani
Journal:  Neurochem Res       Date:  2013-10-20       Impact factor: 3.996

5.  The changing landscape of voltage-gated calcium channels in neurovascular disorders and in neurodegenerative diseases.

Authors:  Mauro Cataldi
Journal:  Curr Neuropharmacol       Date:  2013-05       Impact factor: 7.363

Review 6.  The SH-SY5Y cell line in Parkinson's disease research: a systematic review.

Authors:  Helena Xicoy; Bé Wieringa; Gerard J M Martens
Journal:  Mol Neurodegener       Date:  2017-01-24       Impact factor: 14.195

Review 7.  Zonisamide: a review of the clinical and experimental evidence for its use in Parkinson's disease.

Authors:  Neeta D Grover; Ramachandra P Limaye; Dilip V Gokhale; Tatyasaheb R Patil
Journal:  Indian J Pharmacol       Date:  2013 Nov-Dec       Impact factor: 1.200

8.  Repositioning again of zonisamide for nerve regeneration.

Authors:  Kinji Ohno; Hideki Yagi; Bisei Ohkawara
Journal:  Neural Regen Res       Date:  2016-04       Impact factor: 5.135

9.  Zonisamide Enhances Neurite Elongation of Primary Motor Neurons and Facilitates Peripheral Nerve Regeneration In Vitro and in a Mouse Model.

Authors:  Hideki Yagi; Bisei Ohkawara; Hiroaki Nakashima; Kenyu Ito; Mikito Tsushima; Hisao Ishii; Kimitoshi Noto; Kyotaro Ohta; Akio Masuda; Shiro Imagama; Naoki Ishiguro; Kinji Ohno
Journal:  PLoS One       Date:  2015-11-16       Impact factor: 3.240

10.  Zonisamide Administration Improves Fatty Acid β-Oxidation in Parkinson's Disease.

Authors:  Shin-Ichi Ueno; Shinji Saiki; Motoki Fujimaki; Haruka Takeshige-Amano; Taku Hatano; Genko Oyama; Kei-Ichi Ishikawa; Akihiro Yamaguchi; Shuko Nojiri; Wado Akamatsu; Nobutaka Hattori
Journal:  Cells       Date:  2018-12-29       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.